Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Why Mind Medicine Stock Is Skyrocketing Today

Source The Motley Fool

Mind Medicine (NASDAQ: MNMD) stock is seeing impressive gains Friday. The company's share price was up 16.9% as of 3:15 p.m. ET and had been up as much as 20.7% on the day earlier in the session.

Mind Medicine's valuation is surging following Robert F. Kennedy Jr.'s approval as health and human services (HHS) secretary in yesterday's Senate vote. Kennedy has previously voiced support for psychedelics as therapeutic treatments.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »

Mind Medicine stock soars on RFK Jr.'s HHS confirmation

In a 52-to-48 vote yesterday, RJK Jr. was approved as the U.S.'s new HHS secretary. Among President Donald Trump's cabinet nominations, Kennedy's confirmation vote was viewed as one of the more likely to fall through. But he was confirmed for the cabinet role with nearly unanimous Republican support. Sen. Mitch McConnell from Kentucky was the only Republican to vote against Kennedy.

RFK Jr. has previously said that he supports the use of psychedelic drugs as therapeutic treatments in some instances. With the new HHS secretary being a supporter of Mind Medicine's core competency, it's possible that the biotech company will have an easier time bringing its products to the market.

What's next for Mind Medicine?

Political dynamics appear to be shifting in Mind Medicine's favor. The clinical-stage biopharmaceutical company has yet to record any revenue, but it's making progress with testing phases for its core treatments.

On Dec. 16, the company published a press release announcing that its phase 3 study for lysergide D-tartrate (LSD) as a treatment for generalized anxiety disorder was scheduled to kick off in the first half of 2025. Then on Jan. 16, the company announced that the first patient in the clinical test had been dosed. Roughly 250 patients are expected to be tested in the trial, and the results are likely to have a big impact on Mind Medicine's share price.

Should you invest $1,000 in Mind Medicine (MindMed) right now?

Before you buy stock in Mind Medicine (MindMed), consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Mind Medicine (MindMed) wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $829,128!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

Learn more »

*Stock Advisor returns as of February 7, 2025

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

Gold Price Forecast: Gold Plunges to Seven-Week Low, Can $4,100 Hold? Spot gold (XAUUSD) plunged 4% on Monday to close at $4,114.93 per ounce, hitting an intraday low of $4,110.80, its lowest level since August 5. Heading into Tuesday's Asian trading sessio

Author TradingKey

13 hours ago

Spot gold (XAUUSD) plunged 4% on Monday to close at $4,114.93 per ounce, hitting an intraday low of $4,110.80, its lowest level since August 5. Heading into Tuesday's Asian trading sessio

The 30-year Treasury just hit a 22-year high — and the bond market is not pricing the Fed, it is pricing the deficit The 30-year Treasury yield closed at 5.56% on 28 September, the highest since June 2004, while the 10-year reached 5.24% and the 20-year 5.60%. The curve has steepened roughly 30bp in eight sessions even as October hike odds sit at 70.3%. That gap is the story: the long end is repricing fiscal and inflation risk, not policy. With PCE on Wednesday and payrolls on Friday, here is what the long end is really saying.

Author Irene Q.

15 hours ago

The 30-year Treasury yield closed at 5.56% on 28 September, the highest since June 2004, while the 10-year reached 5.24% and the 20-year 5.60%. The curve has steepened roughly 30bp in eight sessions even as October hike odds sit at 70.3%. That gap is the story: the long end is repricing fiscal and inflation risk, not policy. With PCE on Wednesday and payrolls on Friday, here is what the long end is really saying.

Nvidia's $150 billion buyback landed — and the AI sector fell anyway. That's the signal worth trading Nvidia closed up 1.68% at $228.86 on 28 September after announcing a $150 billion share repurchase authorisation, the largest single corporate buyback on record, while the rest of the AI complex sold off: AMD -3.6%, Micron -2.6%, Meta -4.8% and the Philadelphia Semiconductor Index -1.61%. The divergence is not noise. Capital is rotating toward cash-flow certainty, not abandoning the AI theme. With Micron reporting after the close on 30 September, here is what the split means.

Author Irene Q.

16 hours ago

Nvidia closed up 1.68% at $228.86 on 28 September after announcing a $150 billion share repurchase authorisation, the largest single corporate buyback on record, while the rest of the AI complex sold off: AMD -3.6%, Micron -2.6%, Meta -4.8% and the Philadelphia Semiconductor Index -1.61%. The divergence is not noise. Capital is rotating toward cash-flow certainty, not abandoning the AI theme. With Micron reporting after the close on 30 September, here is what the split means.

RBA set to hike interest rate to 4.60% in September as inflation remains elevated The Reserve Bank of Australia (RBA) is widely expected to raise the Official Cash Rate (OCR) by 25 basis points (bps) to 4.60% from 4.35% on Tuesday, after keeping rates unchanged at its previous two meetings

Author FXStreet

21 hours ago

The Reserve Bank of Australia (RBA) is widely expected to raise the Official Cash Rate (OCR) by 25 basis points (bps) to 4.60% from 4.35% on Tuesday, after keeping rates unchanged at its previous two meetings

Silver Price Forecast: XAG/USD falls like house of cards on Fed’s hawkish narrative Silver price (XAG/USD) is down 4.3% to near $61.50 during the European trading session on Monday. The white metal nosedives as elevated United States (US) Treasury Yields have diminished its appeal.

Author FXStreet

Yesterday 09: 04

Silver price (XAG/USD) is down 4.3% to near $61.50 during the European trading session on Monday. The white metal nosedives as elevated United States (US) Treasury Yields have diminished its appeal.

Popular Symbols